Literature DB >> 9598746

Xanthomonas maltophilia: an emerging pathogen in patients with HIV disease.

R Manfredi1, A Nanetti, M Ferri, F Chiodo.   

Abstract

Fifty-four episodes of Xanthomonas maltophilia infection were observed in 52 HIV-infected patients out of 2062 assessed (2.52%) over a 6-year period: sepsis/bacteraemia in 44 cases, lower airways infection in 5 cases, urinary tract infection and pharyngitis in 2 cases each, and lymph node involvement in one patient. X. maltophilia represented the fourth most common non-mycobacterial bacterial pathogen responsible for bacteraemia in HIV-infected patients: 44 cases out of 721 diagnosed (6.1%). When compared with non-typhoid Salmonella spp. bacteraemia, an increased risk to develop X. maltophilia disseminated infection was seen according to the progression of HIV-related immunodeficiency, the occurrence of leukopenia-neutropenia, central venous catheterization, previous antibiotic and/or corticosteroid treatment, and hospitalization. In 3 patients suffering from concurrent AIDS-related disorders, X. maltophilia infection contributed to death, while a recurrence occurred in 2 cases only. Due to the poor antimicrobial susceptibility of this pathogen (also confirmed in our series), X. maltophilia bacteraemia associated with advanced HIV infection and concurrent risk factors, may represent a potentially severe disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9598746     DOI: 10.1258/0956462981922043

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  2 in total

1.  Isolation of multidrug-resistant Stenotrophomonas maltophilia from cultured yellowtail (Seriola quinqueradiata) from a marine fish farm.

Authors:  Manabu Furushita; Akira Okamoto; Toshimichi Maeda; Michio Ohta; Tsuneo Shiba
Journal:  Appl Environ Microbiol       Date:  2005-09       Impact factor: 4.792

2.  Pseudomonas spp. complications in patients with HIV disease: an eight-year clinical and microbiological survey.

Authors:  R Manfredi; A Nanetti; M Ferri; F Chiodo
Journal:  Eur J Epidemiol       Date:  2000-02       Impact factor: 8.082

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.